• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure.

作者信息

Arenbergerova Monika, Arenberger Petr, Marques Emanual, Gkalpakiotis Spyridon

机构信息

Department of Dermatovenereology, Third Faculty of Medicine, Charles University and University Hospital of Kralovske Vinohrady, Prague, Czech Republic.

出版信息

Int J Dermatol. 2020 Jun;59(6):733-735. doi: 10.1111/ijd.14792. Epub 2020 Feb 3.

DOI:10.1111/ijd.14792
PMID:32012238
Abstract
摘要

相似文献

1
Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure.抗TNF治疗失败后使用布罗达单抗成功治疗顽固性臀部化脓性汗腺炎。
Int J Dermatol. 2020 Jun;59(6):733-735. doi: 10.1111/ijd.14792. Epub 2020 Feb 3.
2
Inverse responses of the skin and nail lesions of psoriatic arthritis to an anti-interleukin-17A antibody and an anti-tumor necrosis factor-α antibody.银屑病关节炎的皮肤和指甲病变对抗白细胞介素-17A抗体和抗肿瘤坏死因子-α抗体的反向反应。
J Dermatol. 2019 Nov;46(11):e440-e441. doi: 10.1111/1346-8138.15006. Epub 2019 Jun 28.
3
Ixekizumab in hidradenitis suppurativa in a psoriatic patient.司库奇尤单抗治疗一名银屑病患者的化脓性汗腺炎
G Ital Dermatol Venereol. 2020 Dec;155(6):788-789. doi: 10.23736/S0392-0488.18.06135-7. Epub 2019 Jan 9.
4
Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab.使用白细胞介素-17A抗体司库奇尤单抗成功治疗重度顽固性化脓性汗腺炎
Acta Derm Venereol. 2018 Jan 12;98(1):151-152. doi: 10.2340/00015555-2794.
5
Tildrakizumab in the treatment of moderate-to-severe hidradenitis suppurativa.替拉珠单抗治疗中度至重度化脓性汗腺炎
Australas J Dermatol. 2020 Nov;61(4):e488-e490. doi: 10.1111/ajd.13377. Epub 2020 Jul 6.
6
Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.一项开放标签、研究者发起的单中心探索性试验，评估抗白细胞介素-17A单克隆抗体司库奇尤单抗用于中度至重度化脓性汗腺炎患者的疗效。
Br J Dermatol. 2019 Sep;181(3):609-611. doi: 10.1111/bjd.17822. Epub 2019 May 12.
7
Analysis of Characteristics and Trends in Treatment Response of Hidradenitis Suppurativa Patients: A Southern US Cohort Study.分析南方美国队列研究中化脓性汗腺炎患者治疗反应的特征和趋势。
Dermatology. 2020;236(5):413-420. doi: 10.1159/000504843. Epub 2020 Jan 14.
8
Pharmaceutical Benefits Scheme listing of adalimumab for hidradenitis suppurativa: Is hidradenitis suppurativa a life-changing drug or does lifestyle change the drug?阿达木单抗用于化脓性汗腺炎的药品福利计划清单：化脓性汗腺炎是一种改变生活的药物，还是生活方式改变了药物？
Australas J Dermatol. 2018 Aug;59(3):e243-e244. doi: 10.1111/ajd.12767. Epub 2017 Dec 29.
9
Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.用阿达木单抗治疗重度顽固性化脓性汗腺炎。
J Dtsch Dermatol Ges. 2009 Feb;7(2):139-41. doi: 10.1111/j.1610-0387.2008.06918.x.
10
The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: a systematic review.TNF-α 抑制剂治疗重度化脓性汗腺炎的超适应证治疗：系统评价。
J Dermatolog Treat. 2013 Oct;24(5):392-404. doi: 10.3109/09546634.2012.674193. Epub 2012 Apr 12.

引用本文的文献

1
Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa.白细胞介素-17抑制剂在化脓性汗腺炎治疗中的应用
BioDrugs. 2025 Jan;39(1):53-74. doi: 10.1007/s40259-024-00687-w. Epub 2024 Nov 28.
2
Hidradenitis Suppurativa: A Review of the Biologic and Small Molecule Immunomodulatory Treatments.化脓性汗腺炎：生物制剂和小分子免疫调节治疗综述
J Cutan Med Surg. 2025 Jan-Feb;29(1):NP1-NP20. doi: 10.1177/12034754241300292. Epub 2024 Nov 27.
3
IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa.
白细胞介素-17抑制：化脓性汗腺炎治疗中的有效治疗策略。
Pharmaceutics. 2023 Oct 11;15(10):2450. doi: 10.3390/pharmaceutics15102450.
4
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.化脓性汗腺炎的新兴治疗方法及临床试验概况 第一部分：局部和全身药物治疗
Dermatol Ther (Heidelb). 2023 Aug;13(8):1661-1697. doi: 10.1007/s13555-023-00956-6. Epub 2023 Jul 4.
5
New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.深入了解化脓性汗腺炎的分子发病机制和免疫调节治疗。
Int J Mol Sci. 2023 May 8;24(9):8428. doi: 10.3390/ijms24098428.
6
Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.免疫调节药物治疗化脓性汗腺炎：可能性与局限性。
Int J Mol Sci. 2022 Aug 26;23(17):9716. doi: 10.3390/ijms23179716.
7
IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.IL-17A 是中重度化脓性汗腺炎的一个有针对性的治疗靶点：临床前和 II 期概念验证研究的综合结果。
Exp Dermatol. 2022 Oct;31(10):1522-1532. doi: 10.1111/exd.14619. Epub 2022 Aug 19.
8
New perspectives on the treatment of hidradenitis suppurativa.化脓性汗腺炎治疗的新视角。
Ther Adv Chronic Dis. 2021 Nov 23;12:20406223211055920. doi: 10.1177/20406223211055920. eCollection 2021.
9
Insights into the Pathogenesis of HS and Therapeutical Approaches.化脓性汗腺炎发病机制及治疗方法的见解。
Biomedicines. 2021 Sep 6;9(9):1168. doi: 10.3390/biomedicines9091168.